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Abstract Rheumatoid arthritis (RA) is associated with
increased cardiovascular morbidity and mortality. Micro-
vascular function has been linked to several risk factors for
cardiovascular disease and may be affected in RA. It is,
however, presently unknown at what point in the disease
course the abnormalities in microvascular function occur.
We determined whether microvascular function is already
disturbed in early disease-modifying antirheumatic drugs
(DMARD)-naive RA patients with low systemic inflamma-
tion. Fifteen consecutive RA patients with a median
symptom duration of 5 months, a C-reactive protein level
of ≤20 mg/l and without a history of cardiovascular disease,
and age 15 and sex-matched healthy controls were
recruited. Endothelium-dependent and endothelium-
independent vasodilatation in skin was evaluated with laser
Doppler fluxmetry after iontophoresis of acetylcholine and
sodium nitroprusside, respectively. Videomicroscopy was
used to measure recruitment of skin capillaries after arterial
occlusion. CRP and ESR levels were mildly, but signifi-
c a n t l ye l e v a t e di np a t i e n t sc o m p a r e dt oc o n t r o l s .N o
differences in both endothelium-dependent vasodilatation
and capillary recruitment were observed between groups
[709% (95% CI, 457–961%) vs 797% (95% CI, 556–
1,037%), P = 0.59 and 37% (95% CI, 26–47%) vs 41%
(95% CI, 31–50%), P=0.59, respectively]. Skin microvas-
cular function is preserved in early, DMARD-naive RA
patients with moderately active RA but low systemic
inflammatory activity. Both the extent of the systemic
inflammation and disease duration, therefore, may be
important determinants of microvascular dysfunction and




Cardiovascular disease (CVD) has been recognized as the
major cause of excess morbidity and mortality in patients
with rheumatoid arthritis (RA) [1–3]. This increased
cardiovascular risk in RA may partly be due to traditional
cardiovascular risk factors, i.e., an atherogenic lipid profile
and hypertension [4], but chronic inflammation is also
thought to be important [5–9].
Inflammation-induced vascular dysfunction of the
macrocirculation and microcirculation, in particular im-
paired endothelium-dependent vasodilatation, may pre-
dispose RA patients to CVD [4, 10, 11]. Macrovascular
endothelial dysfunction precedes and initiates atheroscle-
rosis and is a predictor of long-term cardiovascular risk
[12]. Microvascular endothelial dysfunction, on the other
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DOI 10.1007/s10067-011-1750-1hand, is important not only in the development of target
organ damage in the heart and kidney, but also in the
development of cardiovascular risk factors such as
hypertension and insulin resistance [13–15]. Progressive
impairment of microvascular endothelium-dependent va-
sodilatation of the skin is associated with an increasing
coronary heart disease risk [16].
In longstanding RA, microvascular endothelium-
dependent vasodilatation is impaired and associated with
increased C-reactive protein (CRP) levels [17–19]. More-
over, anti-inflammatory therapy improves both peripheral
(cutaneous) and myocardial microvascular dysfunction in
RA patients [20, 21]. This underlines the fact that the
atherogenic process is not limited to plaque formation in
large conduit vessels but is associated also with impaired
microvascular function that plays an important role in
regulating tissue perfusion, including myocardial perfusion
and associated ischemia.
An intriguing question is at what point in the inflamma-
tory disease course abnormalities in (micro)vascular func-
tion occur. Impaired microvascular endothelium-dependent
vasodilatation can be demonstrated in patients with
longstanding RA with low disease activity [20]. In
addition, a flare of inflammatory activity in RA patients
impairs microvascular endothelium-dependent vasodilata-
tion even more, whereas inflammatory suppression does
not restore vasoreactivity completely to normal [21]. In
newly diagnosed RA patients and high systemic inflam-
mation, both endothelium-dependent and endothelium-
independent vasodilatation of the resistance vessels are
impaired as assessed with venous occlusion plethysmog-
raphy [10].
It is presently unknown whether microvascular dysfunc-
tion is already present in early DMARD-naive RA patients
with moderate disease but low systemic inflammatory
activity. The aim of the study was to establish whether
microvascular endothelium-dependent vasodilatation and
capillary recruitment is impaired in patients with very early,
DMARD-naive RA with low systemic inflammation com-




Fifteen consecutive eligible patients (12 females) with RA
were studied. Diagnosis was confirmed using the 1987
ACR criteria, [22] and low systemic inflammatory activity
was defined as a CRP level ≤20 mg/l. The vascular
function study was performed <2 weeks after the
diagnosis of RA and prior to treatment with disease-
modifying anti-rheumatic drugs (DMARDs) or oral
corticosteroids. A total of 15 age- and sex-matched
healthy subjects were studied as a control group. Clinical
and biochemical characteristics of the study groups are
s h o w ni nT a b l e1. Exclusion criteria were diabetes
mellitus, hypertension, history of cardiovascular disease,
Raynaud’s syndrome, scleroderma, concurrent infection,
thyroid dysfunction, and current or recent medication
which might affect vascular function, except non-
steroidal anti-inflammatory drugs.
All participants gave written informed consent and the
study protocol was approved by the Medical Ethics
Committee of the Slotervaart Hospital, Jan van Breemen
Institute and BovenIJ Hospital.
Study design
Microvascular measurements were conducted in a quiet,
temperature-controlled room (T=23.4±0.4°C) after 20–
30 min of acclimatization, with the subjects in the sitting
position and the investigated non-dominant hand at heart
level. Nailfold capillary studies and iontophoresis studies
were performed on the same day by a single experienced
investigator (IvE). Subjects were asked to refrain from
beverages other than water (especially no caffeine or
alcohol), smoking, medication except acetaminophen if
necessary, and meals from midnight at the testing day.
Nailfold capillaries in the dorsal skin of the third finger
were visualized by a capillary microscope as previously
described [23, 24]. Nailfold capillaries were recorded on
videotape before and after 4 min of arterial occlusion with a
digital cuff. This procedure was performed twice, and the
mean of both measurements was used for analyses. In
addition, venous congestion, with the digital cuff inflated to
60 mmHg for 60 s, was applied to expose a maximal
number of non-perfused capillaries. Capillaries were
counted by a single observer using the naked eye from a
freeze-framed reproduction of the videotape and from the
running videotape, when it was uncertain whether a
capillary was present or not. Baseline capillary density
was defined as the number of continuously erythrocyte-
perfused capillaries during a 15-s period. Intermittently
perfused capillaries were also visible and are proposed to
form an important functional reserve that can be recruited
during post-occlusive hyperemia. The maximum number of
capillaries visible directly after cuff release was counted for
30 s. Post-occlusive capillary recruitment was calculated by
dividing the increase in density by the baseline density. The
day to day coefficient of variation (CV) of the capillary
density in resting state was 2.3±1.8%. The CV of the
1114 Clin Rheumatol (2011) 30:1113–1118percentage capillary recruitment and absolute capillary
recruitment during post-occlusive hyperemia were 8.3±
4.9% and 6.2±4.3%, respectively.
Endothelium-(in)dependent vasodilatation of forearm
skin microcirculation was evaluated by iontophoresis of
acetylcholine and sodium nitroprusside in combination with
laser Doppler fluxmetry as previously described in more
detail [23, 25]. Acetylcholine (1%, Miochol-E, Théa
Pharma, Zoetermeer, the Netherlands) was delivered with
an anodal current; seven doses (0.1 mA for 20 s) were
delivered, with a 60-s interval between each dose. Sodium
nitroprusside (0.01%, Haagse ziekenhuis apotheek) was
delivered with a cathodal current; nine doses (0.2 mA for
20 s) were delivered, with a 90-s interval between each
dose. Acetylcholine-dependent laser Doppler flux was
measured on the non-dominant forearm, whereas
nitroprusside-dependent laser Doppler flux was measured
at the same spot on the opposite forearm, with approxi-
mately 15 min elapsed between the two measurements. The
day to day CV of the percentage increase from baseline to
the final 2 min of the plateau phase was 9.8±5.6% for
acetylcholine and 8.3±5.4% for sodium nitroprusside.
Assessment of inflammatory parameters
Disease activity was measured by calculating the disease
activity score of 28 joints (DAS28) [26]. CRP levels were
determined using the Roche/Hitachi cobas 6000 analyzer,
based on the principle of particle-enhanced immunolog-
ical agglutination (Roche Diagnostics GmbH, D-68298,
Mannheim, Germany). Values are expressed in milli-
grams/litre. A CRP below 10 mg/L was considered to be
normal. ESR was determined with local measurement
techniques (Westergren method) and expressed in milli-
meter per hour.
Statistical analyses
Data are expressed as mean (SD) or median (range) as
appropriate. The distribution of variables was tested for
normality and transformed if necessary. Student’s t test was
used to compare continuous normally distributed variables
within patients and matched controls. We used non-
parametric Mann–Whitney U tests when appropriate. For
dichotomous variables, Pearson chi-square test was used.
Correlations between variables were analysed by using
Pearson correlation or Spearman’s rho tests when appropri-
ate. A two-tailed probability value of P<0.05 was
considered (statistically) significant.
Power calculations based on repeat microvascular
endothelium-dependent responses measured at two-time
points 3 months apart in 23 individuals [27], suggest that
it is possible to detect a difference of 270% points with
85% power at P<0.05 change using a paired comparison in
15 patients.





Age, years 48±10 48±10 0.92
Female, n (%) 12 (80) 12 (80) N/A
Symptom duration, months 5 (4–12) N/A N/A
Rheumatoid factor (RF) positive, n (%) 11 (73) N/A N/A
ACPA positive, n (%) 13 (87) N/A N/A
Erosive, n (%) 3 (20) N/A N/A
Disease activity score (DAS28) 4.7 (0.95) N/A N/A
ESR, mm/h 18 (11–35) 5 (3–8) <0.001
CRP, mg/l 3 (2–17) 1 (1–2) 0.002
Fasting glucose 4.8 (4.2–5.3) 4.5 (4.2–4.7) 0.38
Total cholesterol 4.7 (4.0–5.3) 5.4 (4.1–5.7) 0.42
HDL-c 1.52 (1.31–1.87) 1.42 (1.27–1.88) 0.78
LDL-c 2.70 (2.11–3.37) 2.72 (2.01–3.88) 0.68
Triglycerides 1.01 (0.78–1.78) 0.99 (0.58–1.31) 0.26
Systolic blood pressure, mmHg 126±15 118±7 0.1
Diastolic blood pressure, mmHg 80±8 79±6 1.0
Smoking (%) 2 (13) 1 (7) 0.5
NSAID use, n (%) 10 (67) N/A N/A
Body mass index (BMI) 24.5 (22.4–27.4) 24.4 (22.1–25.2) 0.42
Table 1 Baseline characteristics
of the RA patients and controls
Data are mean +/−SD or median
(interquartile range); pulse
pressure = systolic blood pres-
sure − diastolic blood pressure
ACPA anti-citrullinated protein/
peptide antibodies, ESR erythro-






drug, N/A not applicable
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Characteristics
Baseline, demographic, and clinical characteristics of
patients are shown in Table 1. The mean DAS28 score
was 4.7 and CRP and ESR levels were significantly higher
in patients compared to controls. The median symptom
duration was 5 months.
Microvascular function is not disturbed in very early
untreated arthritis
Endothelial (in)dependent vasodilatation
Microvascular vasodilatation in response to acetylcholine
(endothelium dependent) in RA patients was comparable to
controls [709% (95% CI, 457–961%) vs 797% (95% CI,
556–1,037%), P=0.59; Table 2 and Fig. 1]. The response to
sodium nitroprusside (endothelium independent) also did
not differ significantly between patients and controls
[1,292% (95% CI, 865–1,720%) vs 1,094% (95% CI,
741–1,448%), P=0.45].
Capillary density and recruitment
Baseline capillary density was similar in both groups,
49/mm
2 in patients vs 46/mm
2 in controls. The absolute
and relative post- ischemic capillary recruitment did not
differ between patients and controls (17 vs 18 mm
2,
respectively for absolute increase, P=0.79 and 37% (95%
CI, 26–47%) vs 41% (95% CI, 31–50%), respectively for
relative increase, P=0.56). The total number of anatom-
ically present capillaries visible after venous occlusion
w a s7 2i np a t i e n t sv s6 8i nc o n t r o l s ,w h i c hw a sn o t
different (P=0.56; Table 2,F i g .2).
Fig. 2 Capillary recruitment depicted as the percentual increase of
visible capillary numbers between baseline and after post-occlusive
hyperaemia
Fig. 1 Acetylcholine-mediated vasodilatation in controls and RA
patients. The mean of vasodilatation, indicated by the horizontal line,
is comparable in patients and controls. ACh acetylcholine
RA patients Healthy controls P value
Ach-mediated vasodilatation n=15 n=15
Skin temperature, °C 30.3±0.9 29.9±0.7 0.12
Baseline skin perfusion, PU 8.5 (3.7–14.5) 6.8 (4.6–8.0) 0.58
Ach-mediated vasodilatation, % 709±454 797±435 0.59
SNP-mediated vasodilatation
Skin temperature, °C 30.0±0.9 29.8±0.8 0.47
Baseline skin perfusion, PU 5.3 (3.6–7.3) 6.7 (5.1–9.6) 0.25
SNP-mediated vasodilatation, % 1,292±772 1,094±638 0.45
Capillary recruitment n=14 n=15
Skin temperature, °C 30.2±1.4 29.7±1.3 0.24
Baseline capillary density, number/mm² 49±11 46±12 0.57
Peak capillary density, number/mm² 66±15 64±16 0.80
Venous occlusion, number/mm
2 72±16 68±18 0.56
Absolute increase, number/mm² 17±8 18±8 0.79
Capillary recruitment, % 37±18 41±18 0.56
Table 2 Microvascular
measurement
Peak capillary density was
defined as the maximum number
of capillaries visible directly
after arterial occlusion during
post-ischemic hyperaemia.
Venous occlusion represents the
maximal number of non-
perfused capillaries exposed
after venous congestion. Data
are mean +/− SD or median
(interquartile range). Variables
were tested using Student’s t test
or Mann–Whitney U test
RA rheumatoid arthritis, Ach
aceltycholine, SNP sodium
nitroprusside
1116 Clin Rheumatol (2011) 30:1113–1118No correlations between microvascular function
and disease activity markers and symptom duration
We did not find significant correlations between CRP or
ESR or DAS28 and endothelium-dependent vasodilatation
or capillary recruitment. The endothelium-dependent vaso-
dilatation and capillary recruitment did not correlate
significantly with symptom duration.
Discussion
In the present study, we observed a preserved microvascular
endothelium-dependent vasodilatation and capillary recruit-
ment during reactive hyperemia in DMARD-naive patients
with newly diagnosed RA and low systemic inflammatory
activity. Peripheral and coronary microvascular dysfunction
is considered important in the development of cardiovas-
cular disease [14, 28]. Previous studies demonstrated that
coronary and peripheral microvascular dysfunction is
apparent in longstanding established RA with high, but
also low inflammatory activity [11, 18, 19]. Moreover, anti-
inflammatory therapy improves microvascular function, but
does not completely restore it [18, 24]. This persisting
microvascular dysfunction may be caused by cumulative
effects of inflammation, which in the long run lead to
irreversible vascular damage. The finding of an inverse
association between coronary microvascular function and
disease duration in RA is compatible with such an
explanation [20]. On the other hand, microvascular dys-
function may already be present at the time of diagnosis
because subtle increased levels sometimes within the
normal range of C-reactive protein can already be detected
years before the onset of clinical RA [29]. Our findings,
however, do not support this, as we found preserved
microvascular function in patients with newly diagnosed,
moderately severe RA with low systemic inflammatory
activity. Interestingly, the CRP levels in our newly
diagnosed RA patients are comparable to the CRP levels
(4.2 mg/L) of patients with longstanding RA demonstrating
impaired coronary microvascular function [20], suggesting
that disease duration is an independent determinant of
microvascular function. Nevertheless, newly diagnosed
patients with RA do exhibit impaired endothelium-
dependent and endothelium-independent vasodilatation of
small arteries and resistance vessels if systemic inflamma-
tory activity is more pronounced (i.e., CRP 29±10 mg/L)
[10]. Moreover, suppression of inflammatory activity seems
to restore vasodilatory function [10]. These findings,
together with our finding, suggest that systemic inflamma-
tory activity is necessary to cause microvascular dysfunc-
tion, which is reversible early in the disease course, but
becomes irreversible after a longer disease duration.
Obviously, with relatively low patient numbers, a type 2
error may occur more easily. Although we cannot com-
pletely exclude a difference in endothelium-dependent
vasodilatation between RA patients and control subjects, it
should be realized that the observed difference was very
small (88 percentage point difference). To put this differ-
ence in perspective, in patients with longstanding RA,
hypertension, obesity, or individuals at increased coro-
nary heart disease risk, the difference in endothelium-
dependent vasodilatation, as compared with healthy
controls, exceeds 300 percentage points [16, 18, 25, 30].
In conclusion, the present study showed that skin
microvascular function is not impaired in very early
DMARD-naive RA patients with low systemic inflamma-
tion, compared to healthy controls.
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